Proposed algorithm for the management of RT DLBCL in the era of novel agents of CLL. Bcl-2i, Bcl-2 inhibitor; BTKi, BTK inhibitor; CR, complete response; treat as de novo DLBCL, typically R-CHOP or R-CHOP like regimens.